Efficacy and Safety of Isatuximab Plus VRd in Patients With Newly Diagnosed Multiple Myeloma Ineligible/With No Immediate Intent for ASCT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
Leukemia 2023 Jul 01;37(7)1521-1529, EM Ocio, A Perrot, P Bories, JF San-Miguel, IW Blau, L Karlin, J Martinez-Lopez, SY Wang, S Bringhen, M Marcatti, MV Mateos, P Rodriguez-Otero, S Oliva, A Nogai, N Le Roux, L Dong, S Macé, M Gassiot, T Fitzmaurice, C Oprea, P MoreauFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.